Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | CCR9 | P51686 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CCR2 | P41597 | 5/20 | 0.52 |
| ▸ | RHEB | Q15382 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31623397 | 1.00 | MCL1 (0.62) | MCL1GPR35CCR9KDM4EALDH1A1 | |
| SCHEMBL31623400 | 1.00 | MCL1 (0.62) | MCL1GPR35CCR9KDM4EALDH1A1 | |
| SCHEMBL3499318 | 0.87 | MCL1 (0.55) | MCL1GPR35CCR9KDM4EALDH1A1 | |
| SCHEMBL43328 | 0.86 | KDM4E (0.66) | MCL1GPR35KDM4EALDH1A1HPGD | |
| SCHEMBL29834934 | 0.82 | L3MBTL1 (0.57) | MCL1CCR9KDM4EALDH1A1HPGD | |
| SCHEMBL20646750 | 0.82 | RXFP1 (0.46) | MCL1CCR9CCR2RXFP1PHGDH | |
| SCHEMBL4833633 | 0.82 | L3MBTL1 (0.57) | MCL1CCR9KDM4EALDH1A1HPGD | |
| SCHEMBL8959246 | 0.81 | RXFP1 (0.55) | CCR9KDM4EALDH1A1CCR2RXFP1 | |
| SCHEMBL10254076 | 0.81 | MCL1 (0.64) | MCL1GPR35CCR9KDM4EALDH1A1 | |
| SCHEMBL3061835 | 0.81 | MCL1 (0.64) | MCL1GPR35KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4511835-B2 | — | — | 2010-07-28 | — | — | JP | claimed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | claimed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | claimed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| WO-2025129023-A1 | INDOLE AMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12065428-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| WO-2023043816-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-1148881-A1 | USE OF PYRIDAZINO [4,5-(b)]-INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS | Sanofi-Aventis (FR) | 2001-10-31 | — | — | EP | disclosed |
| CN-1265108-A | 4-oxo-3,5-dihydro-4H-pyridazino [4,5-b]-indole-1-acetamide derivatives, their prepn. and their application in therapy | SANOFI SYNTHELABO (FR) | 2000-08-30 | — | — | CN | disclosed |
| WO-2000044384-A1 | USE OF PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS | SANOFI-SYNTHELABO (FR) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044751-A1 | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2000-08-03 | — | — | WO | disclosed |
| EP-1000063-A1 | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO 4,5-$i(b)]-INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-SYNTHELABO (FR) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006406-A1 | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]-INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | MCL1 339/4885GPR35 1085/4885CCR9 144/4885 |
| US-12065428-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885GPR35 4033/4885CCR9 735/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885GPR35 4033/4885CCR9 735/4885 |
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | MCL1 870/4885GPR35 2087/4885CCR9 2475/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | MCL1 3552/4885GPR35 674/4885CCR9 1460/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | MCL1 319/4885GPR35 1144/4885CCR9 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.